Strategic expansion Vivasure Medical is part of Haemonetics and is actively pursuing regulatory approvals in Europe and the United States for its fully absorbable, patch-based large-bore vessel closure devices, presenting opportunities for cross-promotion, co-marketing, and distribution partnerships with Haemonetics and other TCT-focused channels.

Regulatory momentum Recent European CE mark approval for the PerQseal Elite and ongoing U.S. IDE PATCH Pivotal studies indicate continued regulatory activity, suggesting potential sales windows in Europe and the US for hospital systems, cardiology centers, and vascular labs adopting advanced large-bore closure technology.

Clinical validation Positive early results from pivotal studies and a focus on bioresorbable, sutureless closure position the device as a compelling option for operators seeking reduced complication risk and faster recovery, signaling opportunities with interventional cardiology and vascular surgery teams.

Strategic funding Strong funding history including Series D support and Haemonetics investment underpin a scalable commercial plan, enabling accelerated market access initiatives, clinical adoption programs, and potential co-development opportunities with partners targeting large-bore access markets.

Market positioning Distinctive technology for large-bore arteriotomies and ongoing development of PerQseal Blue for venous closures create cross-sell and adjacent-market expansion opportunities with hospitals and medtech distributors serving TAVR/TMVR/TTVR programs and other percutaneous interventions.